Share-based Payment Arrangement, Expense of vTv Therapeutics Inc. from 30 Sep 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
vTv Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2015 to 30 Sep 2025.
  • vTv Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,007,000, a 18% increase year-over-year.
  • vTv Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,575,000, a 53% increase year-over-year.
  • vTv Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,757,000, a 75% increase from 2023.
  • vTv Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,578,000, a 24% increase from 2022.
  • vTv Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,272,000, a 46% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

vTv Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,575,000 $1,007,000 +$154,000 +18% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $3,421,000 $930,000 +$71,000 +8.3% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $3,350,000 $813,000 +$593,000 +270% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $2,757,000 $825,000 +$422,000 +105% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $2,335,000 $853,000 +$420,000 +97% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $1,915,000 $859,000 +$460,000 +115% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $1,455,000 $220,000 -$123,000 -36% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,578,000 $403,000 +$112,000 +38% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $1,466,000 $433,000 +$95,000 +28% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $1,371,000 $399,000 +$232,000 +139% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,139,000 $343,000 -$133,000 -28% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $1,272,000 $291,000 -$703,000 -71% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2025 2024 FY
Q3 2022 $1,975,000 $338,000 -$136,000 -29% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $2,111,000 $167,000 -$285,000 -63% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $2,396,000 $476,000 +$40,000 +9.2% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,356,000 $994,000 +$722,000 +265% 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
Q3 2021 $1,634,000 $474,000 +$303,000 +177% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,331,000 $452,000 +$266,000 +143% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $1,065,000 $436,000 +$56,000 +15% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $1,009,000 $272,000 -$151,000 -36% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
Q3 2020 $1,160,000 $171,000 -$242,000 -59% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $1,402,000 $186,000 -$215,000 -54% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $1,617,000 $380,000 +$99,000 +35% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $1,518,000 $423,000 +$92,000 +28% 01 Oct 2019 31 Dec 2019 10-K 29 Mar 2022 2021 FY
Q3 2019 $1,426,000 $413,000 -$166,000 -29% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,592,000 $401,000 -$402,000 -50% 01 Apr 2019 30 Jun 2019 10-Q 03 Aug 2020 2020 Q2
Q1 2019 $1,994,000 $281,000 -$682,000 -71% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,676,000 $331,000 -$715,000 -68% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $3,391,000 $579,000 -$380,000 -40% 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2019 2019 Q3
Q2 2018 $3,771,000 $803,000 -$156,000 -16% 01 Apr 2018 30 Jun 2018 10-Q 31 Jul 2019 2019 Q2
Q1 2018 $3,927,000 $963,000 +$282,000 +41% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q4 2017 $3,645,000 $1,046,000 +$392,000 +60% 01 Oct 2017 31 Dec 2017 10-K 21 Feb 2020 2019 FY
Q3 2017 $3,253,000 $959,000 +$278,000 +41% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,975,000 $959,000 +$260,000 +37% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018 2018 Q2
Q1 2017 $2,715,000 $681,000 +$74,000 +12% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q4 2016 $2,641,000 $654,000 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $681,000 +$377,000 +124% 01 Jul 2016 30 Sep 2016 10-Q 01 Nov 2017 2017 Q3
Q2 2016 $699,000 01 Apr 2016 30 Jun 2016 10-Q 02 Aug 2017 2017 Q2
Q1 2016 $607,000 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q3 2015 $304,000 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3

vTv Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,757,000 +$1,179,000 +75% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $1,578,000 +$306,000 +24% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $1,272,000 -$1,084,000 -46% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2025 2024 FY
2021 $2,356,000 +$1,347,000 +133% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
2020 $1,009,000 -$509,000 -34% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
2019 $1,518,000 -$1,158,000 -43% 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2022 2021 FY
2018 $2,676,000 -$969,000 -27% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $3,645,000 +$1,004,000 +38% 01 Jan 2017 31 Dec 2017 10-K 21 Feb 2020 2019 FY
2016 $2,641,000 +$1,782,000 +207% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
2015 $859,000 01 Jan 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.